Brought to you by 
Kallyope closes $66mm Series B
05 Dec 2018
Executive Summary
Kallyope Inc. (therapies involving the gut-brain axis) raised $66mm in its Series B financing from returning shareholders Lux Capital, Column Group, Polaris Partners, Illumina Ventures, and Alexandria Venture Investments, and new backers Euclidean Capital and Two Sigma Ventures. The company has early-stage programs aimed at modulation of gut-brain circuits. Kallyope will initially focus on therapies for metabolic, gastrointestinal, and neurological diseases.
Deal Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kallyope closes $66mm Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice